KRAS and pancreatic neoplasm: Compounds that stabilized the KRAS G4 in the FRET Melt2 assay were further tested in KRAS-dependent AsPc1 pancreatic cancer cells for their 72 h cytotoxicity (Figure 3C) and their correlating regulation of KRAS transcription (Figure 3D).